Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
China · Delayed Price · Currency is CNY 85.00
-2.70 (-3.08%)
Sep 11, 2026, 3:00 PM CST
Beijing Hotgen Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,478 | 14,391 | 5,540 | 3,670 | 5,606 | 7,224 | |
Market Cap Growth | -52.33% | 159.78% | 50.94% | -34.53% | -22.40% | 197.90% |
Enterprise Value | 6,427 | 13,345 | 4,538 | 3,094 | 3,942 | 5,855 |
Last Close Price | 85.00 | 162.00 | 61.84 | 40.73 | 60.43 | 74.87 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 126.90 | 5.93 | 3.31 |
Forward PE | - | 228.67 | 135.17 | 33.40 | 33.40 | 33.40 |
PS Ratio | 15.95 | 35.54 | 10.87 | 6.70 | 1.58 | 1.35 |
PB Ratio | 2.89 | 5.42 | 1.82 | 1.09 | 1.67 | 2.51 |
P/TBV Ratio | 3.12 | 5.90 | 1.84 | 1.11 | 1.71 | 2.59 |
P/FCF Ratio | - | - | - | - | 13.56 | 3.22 |
P/OCF Ratio | - | - | - | - | 5.73 | 2.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.71 | 32.96 | 8.90 | 5.65 | 1.11 | 1.09 |
EV/EBITDA Ratio | - | - | - | 197.58 | 3.33 | 2.23 |
EV/EBIT Ratio | - | - | - | - | 3.60 | 2.28 |
EV/FCF Ratio | - | - | - | - | 9.53 | 2.61 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | - | - | - | 0.61 | 0.03 | 0.01 |
Debt / FCF Ratio | - | - | - | - | 0.10 | 0.02 |
Net Debt / Equity Ratio | -0.46 | -0.50 | -0.34 | -0.18 | -0.42 | -0.71 |
Net Debt / EBITDA Ratio | 4.85 | 6.79 | 8.40 | -37.74 | -1.20 | -0.78 |
Net Debt / FCF Ratio | 3.97 | 10.37 | 7.29 | 1.28 | -3.44 | -0.91 |
Asset Turnover | 0.15 | 0.12 | 0.15 | 0.15 | 0.94 | 2.36 |
Inventory Turnover | 2.10 | 2.18 | 2.30 | 1.45 | 8.56 | 11.71 |
Quick Ratio | 7.38 | 6.00 | 4.15 | 3.53 | 3.09 | 2.96 |
Current Ratio | 8.13 | 6.44 | 4.59 | 4.47 | 3.52 | 3.43 |
Return on Equity (ROE) | -11.34% | -9.06% | -7.28% | 0.50% | 29.71% | 121.66% |
Return on Assets (ROA) | -6.45% | -5.25% | -3.82% | -0.76% | 18.14% | 70.75% |
Return on Invested Capital (ROIC) | -23.48% | -16.38% | -8.85% | -1.93% | 68.42% | 370.39% |
Return on Capital Employed (ROCE) | -11.30% | -9.40% | -6.90% | -1.30% | 32.30% | 88.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -3.27% | -1.50% | -3.71% | 0.79% | 16.85% | 30.26% |
FCF Yield | -4.04% | -0.88% | -2.58% | -12.58% | 7.38% | 31.09% |
Dividend Yield | - | - | - | 0.49% | - | 4.51% |
Payout Ratio | - | - | - | - | 32.92% | 4.27% |
Buyback Yield / Dilution | -11.00% | -4.99% | 1.29% | 3.88% | 0.14% | 0.12% |
Total Shareholder Return | -11.00% | -4.99% | 1.29% | 4.37% | 0.14% | 4.63% |